

1 **DOI: <https://doi.org/10.47391/JPMA.045>**

2
3 **Dyskeratosis congenita: a case report on a rare disease**

4
5 **Sehar Khaliq, Syed Kumail Hasan Kazmi**

6 Foundation University Medical College, Rawalpindi, Pakistan

7 **Correspondence:** Sehar Khaliq **Email:** seharkhalique@yahoo.com

8
9 **Abstract**

10 Dyskeratosis congenita is a very rare inherited haematological disorder
11 characterised by a classical clinical triad of leukoplakia, skin pigmentation and
12 dystrophied nails. Here is a case of a young patient who presented with brittle
13 nails, lacy hyperpigmentation of the skin and leukoplakia along with
14 pancytopenia. Haematopoietic stem cell transplantation is the only cure for this
15 disease but due to financial constraints of the family it was not possible. The
16 patient was placed on androgen therapy and showed favourable response but later
17 was lost to follow-up.

18 **Keywords:** Dyskeratosis Congenita, Pancytopenia, Leukoplakia

19
20 **Introduction**

21 Dyskeratosis Congenita (DC) is a genetic disorder, the hallmark of which is the
22 typical triad of clinical findings that include abnormal skin pigmentation, nail
23 dystrophy, and leukoplakia. It involves multiple systems, and the patient
24 eventually progresses to bone marrow failure. There is an increased risk of cancer
25 transformation.¹ The median age at diagnosis is between 5-15 years.² The basic
26 underlying pathology is shortened length of the telomere for age. Management
27 and treatment depends on individual patient. The only option that has the
28 possibility to cure is haematopoietic stem cell transplantation (HSCT) but if

29 HSCT is not feasible then androgen therapy can be given. The patient should be
30 monitored at regular intervals for progression of the disease, bone marrow failure
31 and cancer transformation.³

32 It has been observed that most of the very rare diseases are either misdiagnosed
33 or inappropriately managed. Here we report the case of a young girl who
34 presented with the classical clinical triad along with peripheral cytopenias.

35

36 **Case Report**

37 A 20-year-old girl presented to the Haematology OPD of Fauji Foundation
38 Hospital, Rawalpindi, Pakistan in June 2017 with complaints of shortness of
39 breath and generalised weakness. It was her first visit to the hospital. There were
40 no symptoms of weight loss, fever or change in appetite and she had a regular
41 menstrual cycle. She was not taking any medication. She was a student. Her
42 parents were first- cousins; her siblings — a 12-year-old sister and a 10-year-old
43 brother — were normal and healthy and had no significant finding. Although the
44 patient was concerned about nail dystrophy and hyperpigmentation, she had never
45 been to a doctor for these conditions.

46 She had pallor. On oral examination she had a white patch on the tongue which
47 could not be rubbed off, and for which she was referred to a dental surgeon. The
48 dental surgeon reported it to be consistent with oral leukoplakia (figure I). Nails
49 of both hands and feet were dystrophied, brittle and had vertical ridges on them
50 (figure II). Her skin looked dirty but on close examination it had hyperpigmented
51 and a few hypopigmented areas (figure III). The examination of the eyes, ears,
52 nose and throat was also normal. Chest was bilaterally clear. Cardiac examination
53 was also within normal range. Ultra Sound Scan of abdomen/pelvis was also
54 within normal range.

55 Her blood pressure was 120/70 mm Hg, pulse 90/min, respiratory rate was
56 20/min, and she had no fever. She had pancytopenia. Her WBC count was $3 \times$
57 $10^9/L$ (normal reference range: $4-11 \times 10^9/L$) with an absolute neutrophil count

58 of $1.1 \times 10^9/L$ (normal reference range: $2-7 \times 10^9/L$), platelet count was 42×10
59 $^9/L$ (normal reference range: $150-400 \times 10^9/L$) and haemoglobin was 8.8 gm/dL
60 (normal reference range: $12-16 \text{ gm/dL}$). Viral serology for hepatitis B, C and HIV
61 were negative. Serum B12 and folate were normal. Autoimmune profile turned
62 out to be negative. A bone marrow biopsy was conducted, which revealed
63 hypocellular marrow with no abnormal cells. ECG and ultrasound of the abdomen
64 were normal.

65 Her cytogenetic report lacked any structural or numerical chromosomal
66 abnormality. Chromosomal breakage studies did not show any evidence of
67 Fanconi anaemia. Pancytopenia along with a classical triad of oral leukoplakia,
68 dystrophied nail and hyperpigmentation of the neck/chest led to the diagnosis of
69 DC. The main diagnosis was DC, and although the definitive treatment for DC is
70 bone marrow transplant, it could not be done due to financial constraints of the
71 family. The patient was started on Danazol at a dose of 1 mg/kg/day with
72 monitoring of her liver function tests as it could cause liver impairment. She
73 followed-up after three weeks and her haemoglobin was 10.2 gm/dl and platelets
74 had risen to $68 \times 10^9/L$. She reported a feeling of wellbeing and improvement in
75 her dyspnoea. One month later she had her second follow-up visit and showed
76 further improvement her haemoglobin was 11.2 gm/dL and platelet count was 96
77 $\times 10^9/L$ on this visit. The patient's blood counts improved but leukoplakia and
78 nail dystrophy did not show any signs of improvement. She later lost to follow-
79 up.

80

81 **Discussion**

82 The clinical diagnosis of DC is based on the presence of four major features which
83 include the mucocutaneous triad and bone marrow failure. There are associated
84 multisystem features of the disease; for example, developmental delay or mental
85 retardation, pulmonary disease, periodontal disease, epiphora, oesophageal
86 stricture, premature hair greying, hyperhidrosis, or malignant transformation.⁴

87 Differential diagnoses of DC include Fanconi Anaemia and Shwachman-
88 Diamond syndrome. DC is considered a type of aplastic anaemia and the
89 differential diagnosis is with Fanconi anaemia. However, in contrast to DC,
90 Fanconi anaemia is an autosomal dominant condition with concomitant skeletal
91 and renal abnormalities but there no nail dystrophy or oral leukoplakia is seen in
92 Fanconi anaemia.⁵

93 Shwachman-Diamond syndrome is another rare cause of pancytopenia, inherited
94 in an autosomal recessive manner, and usually presents in the first year of life
95 with exocrine pancreatic insufficiency and bone marrow failure. There is no
96 exocrine pancreatic insufficiency in DC and Shwachman-Diamond syndrome
97 lacks the typical DC triad.⁶

98 Dyskeratosis congenita (DC) has autosomal dominant, autosomal recessive and
99 X-linked mode of inheritance. Ten genes have been identified out of which X-
100 linked DKC1 has the most frequent mutation, occurring in approximately 40% of
101 patients.¹ It encodes the nucleolar protein dyskerin which is involved in telomere
102 maintenance and the biogenesis of ribosomes. The underlying pathology of
103 shortened telomeres in DC is due to mutations in the telomere stabilising
104 component. As a result, there is a defect in the renewing and regenerating capacity
105 of the haematopoietic stem cell.³

106 The median age at diagnosis of DC is approximately 15 years. The diagnosis of
107 classical DC requires that out of the triad of dysplastic nails, lacy reticular
108 pigmentation of the upper chest and/or neck, and oral leukoplakia, at least two
109 features are present.²

110 Almost 90 percent of the patients with DC present with dystrophic nails. Our
111 patient reported to have involvement of fingernails before toenails. The dystrophy
112 of the nails could progress to such an extent that it might result in the complete
113 absence of nails.⁷

114 Mucosal leukoplakia is a common occurrence in DC involving the tongue and
115 buccal mucosa.⁷ The leukoplakic areas have an increased risk of cancerous
116 transformation.⁷

117 DC is a multisystem disorder. Pulmonary complications can lead to fibrosis of
118 the lungs and alterations in the pulmonary vasculature. Other systemic
119 complications include liver diseases, neurological ataxia due to cerebellar
120 hypoplasia and ocular and neurological abnormalities, developmental delays and
121 microcephaly.⁸

122 Majority of the DC patients presents with peripheral cytopenia. Bone marrow
123 failure in DC patients is a result of defective dyskeratin that results in a defective
124 regenerating ability of the haematopoietic stem cells.¹ Bone marrow failure is a
125 major cause of death leading to bleeding and infections.¹ In one study, the patient
126 presented with recurrent dysphagia and on further examination was found to have
127 the classical triad which led to the diagnosis of DC. Although dysphagia has been
128 reported in DC, it is not a very usual finding; however, our patient did not have
129 any such complaint.^{9, 10}

130 Ophthalmological consultation is important as DC patients are at the risk of
131 developing conjunctivitis, retinopathy, blepharitis, pterygium, and epiphora,
132 which occurs as a result of lacrimal duct stenosis. Ophthalmological
133 complications occur in almost 50 percent of DC patients, with epiphora being the
134 commonest.¹ Our patient was seen by an ophthalmologist and thus far has normal
135 eye examination.

136 DC patients have a higher incidence of buccal mucosa hyperpigmentation and
137 hypocalcified teeth.¹¹ Leukoplakia carries a risk of squamous cell carcinoma, with
138 30% of the patients progressing to squamous cell carcinoma in 10–30 years.
139 Leukoplakia occurs in almost 90% of the patients, with first manifestation most
140 commonly occurring between the ages of 5 and 14 years.¹² Our patient noticed
141 leukoplakia when she was 10-years old.

142 In another study, a 21-year-old female was diagnosed with DC and she had
143 infantile secondary sexual characters. This patient also had primary
144 amenorrhoea.¹³ Our patient did not complain of amenorrhoea and her
145 gynaecological examination was normal.

146 In a series of 300 patients with DC, the estimated rate of cancer was found to be
147 approximately 10%.⁸

148 Among DC patients, the most common type of cancers reported are head and neck
149 malignancies and squamous cell carcinomas (SCC) followed by anorectal,
150 gastrointestinal and pulmonary cancers.³

151 Cases of acute myeloid leukaemia and myelodysplastic syndrome in DC have
152 been reported. The cancers in DC are diagnosed at an early age than their average
153 mean age of presentation.¹⁴

154 Life expectancy ranges from infancy to well into the sixth decade of life. Major
155 causes of morbidity include BMF, cancer and pulmonary complications.¹⁵ The
156 only curative treatment for DC is HSCT. If there is no HLA-matched donor, then
157 androgen should be considered.

158 Our case report will add more information to the existing pool of knowledge of
159 this rare disease.

160 The strength of this case report is the fact that it could lead to a better
161 understanding of this rare disorder. Another strength is that it is the first ever case
162 reported from Pakistan. The limitations of this case report is that the patient could
163 not be followed up for a longer period of time and genetic testing could not be
164 done.

165 The main take away lesson from this case report is that the clinician should always
166 do a thorough physical examination as it would assist in proper diagnosis.

167 Physical examination skills have been underemphasised in the current health care
168 system and if properly done can certainly prevent unnecessary diagnostic testing.

169

170

171 Conclusion

172 Dyskeratosis Congenita is a severe multisystem disorder associated with
173 significant morbidity and mortality. Although DC is a rare disease, diagnosis
174 should not be missed, for which close examination of the mucocutaneous
175 abnormalities is important, and the patient should be monitored regularly for
176 progression to bone marrow failure and other systemic complications. Due to
177 heterogeneity of the disease, it is very important for clinical experts to make a
178 correct diagnosis. A delay or a mistake in diagnosis can lead to inappropriate and
179 inadequate management and increased morbidity and mortality. Close
180 surveillance and monthly self-examination is recommended to monitor
181 progression of disease.

182 Informed consent of the patient was taken for the publication of this case report
183

184 **Disclaimer:** None to declare

185 **Disclosures:** None to declare.

186 **Conflicts of Interest:** None to declare.

187 **Funding sources:** None to declare.
188

189 References

- 190 1. Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of
191 dyskeratosis congenita: a review. *J Blood Med* 2014; 5:157–67.
- 192 2. Drachtman RA, Alter BP. Dyskeratosis congenita: clinical and genetic
193 heterogeneity. Report of a new case and review of the literature. *Am J Pediatr*
194 *Hematol Oncol.* 1992; 14:297–304.
- 195 3. Savage SA. Dyskeratosis Congenita. 2009 Nov 12 [Updated 2019 Nov 21].
196 In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet].
197 Seattle (WA): University of Washington, Seattle; 1993-2019. (cited 28th Nov
198 2019) Available from: <https://www.ncbi.nlm.nih.gov/books/NBK22301>.
- 199 4. Dokal I. Dyskeratosis congenita. *Hematol-Am Soc Hemat.* 2011;480–86.

- 200 5. Butturini A, Gale RP, Verlander PC et al. Hematologic abnormalities in Fanconi
201 anaemia: An International Fanconi Anaemia Registry Study. *Blood*. 1994;
202 84:1650–55.
- 203 6. Boocock GR, Morrison JA, Popovic M, Richards N, Ellis L, Durie PR, et al.
204 Mutations in SBDS are associated with Shwachman-Diamond syndrome. *Nat*
205 *Genet*. 2003; 33:97–101.
- 206 7. Changes made on page # 8 line # 204-206, Atkinson JC, Harvey KE, Domingo
207 DL, Trujillo MI, Guadagnini JP, Gollins S, et al.
208 Oral and dental phenotype of dyskeratosis congenita. *Oral Dis*. 2008;14:419-27.
- 209 8. Alter BP, Giri N, Savage SA, Rosenberg PS. Cancer in dyskeratosis congenita.
210 *Blood*. 2009; 113:6549-57
- 211 9. Berezin S, Schwarz SM, Slim MS, Beneck D, Brudnicki AR, Medow MS.
212 Gastrointestinal 5 problems in a child with dyskeratosis congenita. *Am J*
213 *Gastroenterol* 1996; 91:1271-72
- 214 10. Ogden GR, Connor E, Chisholm DM. Dyskeratosiscongenita: Report of a
215 case and review of the literature. *Oral Surg Oral Med Oral Pathol* 1988; 65:586-
216 91
- 217 11. Vulliamy T, Dokal I. Dyskeratosis congenita. *Semin Hematol*. 2006; 43:157–
218 66
- 219 12. Alter BP. Diagnosis, genetics, and management of inherited bone marrow
220 failure syndromes. *Haematology Am Soc Haematol Educ Programme*. 2007;
221 2007:29–39.
- 222 13. Chakrabarti N, Sarma N, Chattopadhyay C, Chowdhuri AR, Das C, Pal SK.
223 A case of dyskeratosis congenita with primary amenorrhea and adenocarcinoma
224 of stomach. *Indian J Dermatol*. 2011; 56:594-96.
- 225 14. Bannon SA, DiNardo CD. Hereditary predispositions to myelodysplastic
226 syndrome. *Int J Mol Sci*. 2016; 17:838
- 227 15. Fernández García MS, Teruya-Feldstein J. The diagnosis and treatment of
228 dyskeratosis congenita: a review. *J Blood Med*. 2014; 5:157-67.

229

230

231



232

233 **Figure: I Patch of Leukoplakia on the anterior surface of the tongue**

234

235

236

237

238

239

240

241

242

243

244

245

246

247

Provisionally Accepted for Publication



248

249 **Figure II: Fingernails showing vertical ridges with dystrophic changes in**
250 **index finger nail.**

251

252 -----

253



254

255 **Figure III: Reticulate Hyperpigmented and a few hypopigmented areas on**
256 **neck and chest**

257